Identifying Potential Cancer Treatments with CT47A8 (G728049)

Target Name: CT47A8

NCBI ID: G728049

CT47A8

Identifying Potential Cancer Treatments with CT47A8

Cancer/testis antigen 47 (CT47A8) is a protein that is expressed in a variety of tissues, including the skin, hair, and nervous system. It is also highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. This protein has been identified as a potential drug target for cancer treatment.

The protein encoded by the CT47A8 gene is a glycoprotein with a molecular weight of approximately 120 kDa. It consists of two heavy chains and two light chains that are held together by disulfide bonds. The heavy chains contain four transmembrane domains, including a N-terminus, a T-terminus, and a middle chain that contains a variety of cytoplasmic domains. The light chains contain a variable region and a constant region that is similar to the heavy chains.

One of the defining features of CT47A8 is its ability to interact with various cell surface molecules. This interactivity has led to the proposal that CT47A8 could be a useful biomarker for cancer diagnosis and treatment. For example, researchers have shown that increasing levels of CT47A8 in cancer cells can inhibit the binding of antibodies to cancer cells, suggesting that it may be a useful target for cancer immunotherapy.

In addition to its potential as a biomarker, CT47A8 has also been identified as a potential drug target. Studies have shown that inhibiting the activity of CT47A8 can lead to the inhibition of various cellular processes that are involved in cancer growth and progression. For example, researchers have shown that the inhibition of CT47A8 can lead to the inhibition of cell proliferation, migration, and invasion. This suggests that CT47A8 could be an effective target for cancer chemotherapy.

Another potential mechanism by which CT47A8 could be targeted for cancer treatment is its role in cell signaling pathways. Studies have shown that CT47A8 is involved in various signaling pathways that are involved in cancer progression, including the TGF-β pathway and the PI3K/Akt pathway. These signaling pathways are involved in the regulation of cell growth, survival, and angiogenesis, and are often targeted by anti-cancer drugs. Therefore, inhibiting the activity of CT47A8 could be an effective way to inhibit the growth and progression of cancer cells.

In conclusion, CT47A8 is a protein that has been identified as a potential drug target for cancer treatment. Its ability to interact with various cell surface molecules and its involvement in various signaling pathways make it an attractive target for cancer immunotherapy and chemotherapy. Further research is needed to fully understand the role of CT47A8 in cancer and to develop effective treatments for this disease.

Protein Name: Cancer/testis Antigen Family 47 Member A8

The "CT47A8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CT47A8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets